| Market Cap | 67.04M | P/E | - | EPS this Y | -254.80% | Ern Qtrly Grth | - |
| Income | 12.16M | Forward P/E | -1.23 | EPS next Y | 31.20% | 50D Avg Chg | 26.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 52.00% |
| Dividend | N/A | Price/Book | 1.26 | EPS next 5Y | - | 52W High Chg | -21.00% |
| Recommedations | 2.50 | Quick Ratio | 15.43 | Shares Outstanding | 44.89M | 52W Low Chg | 171.00% |
| Insider Own | 1.65% | ROA | -40.62% | Shares Float | 29.54M | Beta | 1.24 |
| Inst Own | 60.62% | ROE | 14.29% | Shares Shorted/Prior | 163.16K/143.20K | Price | 1.52 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 3,007,696 | Target Price | 2.00 |
| Oper. Margin | - | Earnings Date | Aug 8 | Volume | 391,025 | Change | 0.00% |
AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Mizuho | Neutral | Dec 18, 23 |
| Wells Fargo | Overweight | Jul 13, 23 |
| Wedbush | Neutral | Jul 12, 23 |
| Mizuho | Buy | Mar 24, 23 |
| Needham | Buy | Mar 24, 23 |
| BTIG | Buy | Dec 8, 22 |
| Needham | Buy | May 17, 22 |
| Barclays | Overweight | May 11, 22 |
| Mizuho | Buy | Jan 6, 22 |